Stock comparison
IDEXX Laboratories
Smith & Nephew
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
SNN
Smith & Nephew
Market cap
$13.01B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | SNN | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 54C | IDXX |
| Benjamin Graham | 80A | 68B | IDXX |
| Philip Fisher | 75B | 45D | IDXX |
| Peter Lynch | 71B | 57C | IDXX |
| Joel Greenblatt | 83C | 33F | IDXX |
| Charlie Munger | 87A | 47D | IDXX |
| Terry Smith | 84A | 49D | IDXX |
Side-by-side metrics
| Metric | IDXX | SNN |
|---|---|---|
| Market cap | $44.12B | $13.01B |
| P/E (TTM) | 39.0x | 20.3x |
| EV/EBIT | 31.6x | 15.5x |
| ROIC (TTM) | 40.66% | 9.11% |
| Gross margin | 62.05% | 68.01% |
| Net margin | 24.63% | 10.14% |
| Revenue CAGR 5y | 7.56% | 4.34% |
| EPS CAGR 5y | 10.79% | 5.03% |
| Debt / Equity | 0.7x | 0.6x |
| Dividend yield | 0.0% | 2.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- ROIC (TTM)40.66%vs 9.11%+78%
- Market cap$44.12Bvs $13.01B+71%
- Net margin24.63%vs 10.14%+59%
- EPS CAGR 5y10.79%vs 5.03%+53%
SNN leads on
- Dividend yield2.62%vs 0.0%+100%
- EV/EBIT15.5xvs 31.6x+51%
- P/E (TTM)20.3xvs 39.0x+48%
- Debt / Equity0.6xvs 0.7x+9%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.